{"id":"89b23d4e-3944-52dc-9a86-d04f495d6c7c","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-msud-drug-response","predicate":"reduces_in_selected_patients","statement":"Phenylbutyrate reduced BCAA/BCKA pools in controls and some late-onset/intermediate MSUD patients; cultured-cell responses did not simply predict the clinical biochemical response.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"4cc008ac-0298-564d-8adb-2755793674f6","mechanism_event_label":"The same drug interaction can help or deplete depending on the disease and remaining enzyme function.","subject":{"id":"59e582c7-8a5b-5bc0-900d-42eb6c0e30be","slug":"sodium-phenylbutyrate","display_name":"Sodium phenylbutyrate","entity_type_key":"drug"},"object":{"id":"7b03f24e-50b1-5b28-885a-18ae5c2b83cc","slug":"human-msud-bcaa-ketoacid-pool","display_name":"BCAA and branched-ketoacid pools in selected MSUD patients","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4cc008ac-0298-564d-8adb-2755793674f6","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-msud-drug-response-event","event_type":"observed_relationship","label":"The same drug interaction can help or deplete depending on the disease and remaining enzyme function.","description":"Phenylbutyrate reduced BCAA/BCKA pools in controls and some late-onset/intermediate MSUD patients; cultured-cell responses did not simply predict the clinical biochemical response.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"59e582c7-8a5b-5bc0-900d-42eb6c0e30be","slug":"sodium-phenylbutyrate","display_name":"Sodium phenylbutyrate","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7b03f24e-50b1-5b28-885a-18ae5c2b83cc","slug":"human-msud-bcaa-ketoacid-pool","display_name":"BCAA and branched-ketoacid pools in selected MSUD patients","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c85b327e-f132-5d9a-8e4b-c2976fcc0373","slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f707c753-cc8c-5f06-90be-bb3d73c60a18","slug":"leucine","display_name":"L-Leucine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"ae40617e-3df7-5d48-8dd2-f16a0d3a8a25","slug":"valine","display_name":"L-Valine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"10548a8b-eb7a-57fe-b86a-05e699591156","slug":"alpha-keto-beta-methylvalerate","display_name":"3-Methyl-2-oxopentanoate","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Small human treatment study plus patient-cell assays.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not universal MSUD efficacy or long-term outcome evidence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Isoleucine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The same drug interaction can help or deplete depending on the disease and remaining enzyme function.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Phenylbutyrate therapy for maple syrup urine disease. · 2011 · https://pubmed.ncbi.nlm.nih.gov/21098507/ · DOI 10.1093/hmg/ddq507","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"89f7a257-b5d9-560f-b9f5-fbd3bbc298ed","evidence_kind":"source_excerpt","locator":"Lines 314-320","start_line":314,"end_line":320,"excerpt":"## isoleucine-msud-drug-response\nThe same drug interaction can help or deplete depending on the disease and remaining enzyme function.\nPhenylbutyrate reduced BCAA/BCKA pools in controls and some late-onset/intermediate MSUD patients; cultured-cell responses did not simply predict the clinical biochemical response.\nModel: Small human treatment study plus patient-cell assays.\nLimitations: Not universal MSUD efficacy or long-term outcome evidence.\nEvidence access: Primary abstract\nPhenylbutyrate therapy for maple syrup urine disease. · 2011 · https://pubmed.ncbi.nlm.nih.gov/21098507/ · DOI 10.1093/hmg/ddq507","model_system":"Small human treatment study plus patient-cell assays.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4b00f118-00fd-5cef-be97-13125eb958e9","stable_key":"import-09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2","title":"L-Isoleucine: transport, translation, catabolism and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"2058ff0da379586994e7fda6ae0086c60fa3173542bfaf1fb3871ad3e09f9c6c","revision_id":"f32192d4-9913-5d35-acbc-cf90ff17995e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}